Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELTAVAC for House Dust Mite Allergic Rhinoconjunctivitis
2024-516893-31-01Phase 3Authorised
- Sponsor
- Probelte Pharma
- Start
- Oct 2024
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC), allergic rhinitis (AR) and allergic conjunctivitis (AC) comparing BELTAVAC polymerized house dust mite extract with Placebo (2 arms). Primary endpoint: Primary: Combined symptom and medication score (CSMS4) for nasal symptoms. Planned start Oct 2024; status: authorised.
02
Drugs
Beltavac
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2024-516893-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516893-31-01.